GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

relacorilant   Click here for help

GtoPdb Ligand ID: 13830

Synonyms: compound 7 [PMID: 28368581] | CORT-125134 | CORT125134 | Lifyorli®
Approved drug Immunopharmacology Ligand
relacorilant is an approved drug
Compound class: Synthetic organic
Comment: Relacorilant (CORT125134; Corcept Therapeutics) is an orally bioavailable selective glucocorticoid receptor (GR) modulator (antagonist) [4]. It was originally developed as a treatment for Cushing syndrome, and was subsequently identified as offering oncology potential, as it was discovered that reducing cortisol signalling can increase tumour sensitivity to chemotherapy [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 106.39
Molecular weight 586.56
XLogP 0.93
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=CC(=CC=N5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
Isomeric SMILES CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
InChI InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
InChI Key WANIDIGFXJFFEL-SANMLTNESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Relacorilant (CORT125134) is being investigated for efficacy as a treatment for Cushing syndrome (endogenous hypercortisolism) [7], and for antitumour activity [1,6]. In 2018 the US FDA granted orphan drug designation for use as a Cushing syndrome therapy and to treat pancreatic cancer. The EU EMA granted orphan designations for these two indications in 2019, followed by OD for the treatment of ovarian cancer in 2023. A combination therapy using relacorilant and nab-paclitaxel was approved by the FDA in March 2026, to treat advanced/previously treated platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02804750 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Phase 2 Interventional Corcept Therapeutics
NCT03776812 Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2 Interventional Corcept Therapeutics
NCT04329949 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Phase 3 Interventional Corcept Therapeutics 1
NCT03697109 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Phase 3 Interventional Corcept Therapeutics The GRACE study
NCT05257408 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Phase 3 Interventional Corcept Therapeutics The ROSELLA trial 2,5-6